Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sinopharm Group Co. Ltd. (SHTDF)
Shanghai, CN
Sinopharm Group Co. Ltd., along with its affiliates, plays a significant role in the People's Republic of China's healthcare sector, primarily engaging in the wholesale and retail trade of pharmaceuticals, medical equipment, and health-related products. The company organizes its extensive operations across four distinct divisions. Its Pharmaceutical Distribution unit supplies a wide array of medicinal products to various clients, including hospitals, other distributors, retail pharmacies, and clinics. This segment also provides comprehensive distribution, logistics, and additional value-added services for both domestic and international pharmaceutical and healthcare product manufacturers and suppliers. The Medical Devices segment is dedicated to the distribution of medical equipment. Through its Retail Pharmacy division, the company oversees and franchises a substantial network of drugstores, which totaled 10,259 locations as of December 31, 2021. The Other Business segment is involved in the manufacturing and sale of pharmaceuticals, chemical reagents, and laboratory supplies. Beyond these core areas, the company's activities extend to property leasing and management; the trade of specialized medical instruments, traditional Chinese herbal medicines, antibiotics, and biological products; information technology development; a variety of consulting services (medicine, health, business, market information); investment management; import and export; and convention and exhibition services. Additionally, it manages medical project investments, consulting, and technology training initiatives. Sinopharm Group Co. Ltd. has formed a strategic partnership with I-Mab to enhance its commercial reach and market transformation efforts. The company was established in 2003, with its headquarters located in Shanghai, China, and operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -0.43% | -15.19% | -9.49% | -11.92% | +5.05% | -32.05% | -31.64% | -46.37% | -30.61% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Distribution: +5.6%-4.1% Q4'25: -3.8% (vs Q4'23)
-
EPS growth Medical - Distribution: +4.9%-0.9% Q4'25: -25.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Distribution: +37.6%+1.7% Q4'25: +15.9% (vs Q4'23)
-
EBIT margin Medical - Distribution: +3.0%+2.9% Q4'25: +3.2% (vs Q4'23)
-
ROIC Medical - Distribution: +5.7%+6.6% ★ Q4'25: +14.5% (vs Q4'23)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: +0.1% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×5.32× Q4'25: 2.45× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 1 EPS Ana. |
Dec 2027 13 Rev. Ana. 1 EPS Ana. |
Dec 2028 8 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
228.67B
est: 230.99B (-1.0%)
|
258.12B
est: 257.69B (+0.2%)
|
277.03B
est: 284.82B (-2.7%)
|
344.53B
est: 298.58B (+15.4%)
|
425.27B
est: 404.38B (+5.2%)
|
456.41B
est: 456.74B (-0.1%)
|
521.05B
est: 526.77B (-1.1%)
|
552.15B
est: 561.22B (-1.6%)
|
596.57B
est: 605.15B (-1.4%)
|
584.51B
est: 598.68B (-2.4%)
|
560.33B
est: 582.36B (-3.8%)
|
611.36B
596.07B – 624.83B
+5.0% YoY
|
639.57B
596.02B – 677.77B
+4.6% YoY
|
672.26B
640.58B – 700.07B
+5.1% YoY
|
| EBITDA |
10.13B
est: 10.35B (-2.2%)
|
12.04B
est: 11.55B (+4.2%)
|
13.43B
est: 12.76B (+5.2%)
|
16.67B
est: 13.38B (+24.6%)
|
20.32B
est: 18.12B (+12.1%)
|
22.62B
est: 20.47B (+10.5%)
|
24.68B
est: 23.61B (+4.6%)
|
26.25B
est: 25.15B (+4.4%)
|
26.90B
est: 27.12B (-0.8%)
|
20.17B
est: 25.26B (-20.1%)
|
20.41B
est: 24.57B (-16.9%)
|
25.79B
25.15B – 26.36B
+5.0% YoY
|
26.98B
25.15B – 28.59B
+4.6% YoY
|
28.36B
27.03B – 29.54B
+5.1% YoY
|
| EBIT |
9.56B
est: 8.76B (+9.1%)
|
10.97B
est: 9.78B (+12.2%)
|
14.02B
est: 10.80B (+29.8%)
|
15.28B
est: 11.33B (+34.9%)
|
17.20B
est: 15.34B (+12.1%)
|
19.02B
est: 17.33B (+9.8%)
|
20.76B
est: 19.98B (+3.9%)
|
22.08B
est: 21.29B (+3.7%)
|
22.47B
est: 22.96B (-2.1%)
|
17.82B
est: 21.19B (-15.9%)
|
16.24B
est: 20.61B (-21.2%)
|
21.64B
21.10B – 22.11B
+5.0% YoY
|
22.64B
21.09B – 23.99B
+4.6% YoY
|
23.79B
22.67B – 24.78B
+5.1% YoY
|
| Net Income |
3.76B
est: 4.14B (-9.1%)
|
4.65B
est: 5.27B (-11.8%)
|
7.87B
est: 5.72B (+37.6%)
|
9.40B
est: 6.11B (+53.9%)
|
10.62B
est: 6.58B (+61.4%)
|
7.19B
est: 7.02B (+2.4%)
|
7.76B
est: 8.05B (-3.6%)
|
8.53B
est: 8.35B (+2.2%)
|
9.05B
est: 8.91B (+1.6%)
|
7.05B
est: 8.13B (-13.3%)
|
6.97B
est: 7.40B (-5.8%)
|
7.83B
7.35B – 8.25B
+5.8% YoY
|
8.47B
7.95B – 8.93B
+8.3% YoY
|
9.26B
8.69B – 9.76B
+9.3% YoY
|
| SGA |
9.75B
est: 10.33B (-5.6%)
|
10.73B
est: 11.53B (-6.9%)
|
11.57B
est: 12.74B (-9.2%)
|
15.89B
est: 13.36B (+19.0%)
|
19.47B
est: 18.09B (+7.6%)
|
21.19B
est: 20.43B (+3.7%)
|
23.20B
est: 23.56B (-1.5%)
|
24.90B
est: 25.10B (-0.8%)
|
26.15B
est: 27.07B (-3.4%)
|
25.57B
est: 26.33B (-2.9%)
|
23.90B
est: 25.61B (-6.7%)
|
26.88B
26.21B – 27.48B
+5.0% YoY
|
28.12B
26.21B – 29.80B
+4.6% YoY
|
29.56B
28.17B – 30.78B
+5.1% YoY
|
| EPS |
1.36
est: 1.33 (+2.6%)
|
1.68
est: 1.69 (-0.5%)
|
2.65
est: 1.83 (+44.6%)
|
3.17
est: 1.96 (+61.9%)
|
3.58
est: 2.11 (+69.7%)
|
2.31
est: 2.25 (+2.7%)
|
2.49
est: 2.58 (-3.4%)
|
2.73
est: 2.67 (+2.1%)
|
2.90
est: 2.86 (+1.6%)
|
2.26
est: 2.60 (-13.2%)
|
2.24
est: 2.37 (-5.5%)
|
2.51
2.35 – 2.64
+5.8% YoY
|
2.72
2.55 – 2.86
+8.3% YoY
|
2.97
2.79 – 3.13
+9.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 1/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Binghua Yang | Executive Director | 322.4K | male |
| Wanyong Lian | President & Executive Director | 216.4K | male |
| Xiaojuan Li | Chief Financial Officer | — | female |
| Yijian Wu | Vice President, Secretary to the Board & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SHTDF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
